Supernus Pharmaceuticals, Inc. · 1 day ago
Senior Manager, Technical Accounting and SEC Reporting
Supernus Pharmaceuticals, Inc. is seeking a Senior Manager, Technical Accounting and SEC Reporting to oversee the preparation and filing of all SEC documents and manage compliance with GAAP and SEC rules. This role involves coordinating with external auditors, managing SOX activities, and providing leadership to ensure effective financial reporting and compliance.
BiotechnologyHealth CarePharmaceutical
Responsibilities
Responsible for the management and preparation of Supernus’ SEC financial statements (periodic reports on Form 10-K, 10-Q) and other SEC filings (Form 4s and 8-Ks, Proxy Statements) in compliance with GAAP and SEC rules:
Prepares the financial statements and drafts notes and management’s discussion and analysis (MDA), including all disclosures. Reviews XBRL tagging. Supports the administration of the Workiva (wDesk) software
Prepares quarterly and year-to-date earnings per share calculations
Researches accounting literature and applies technical standards and analysis of complex or non-recurring transactions and writes technical accounting memos
Monitors and assists in evaluating FASB/SEC/PCAOB reporting developments. Supports accounting initiatives, including financial reporting and disclosure implementation of new standards, as they are released and become effective
Monitors peer group filings to identify industry trends and best practices for disclosures
Assist with the preparation of the earning press release, SEC filings and supports the quarterly Disclosure and Audit Committee meetings
Manages monthly close & SOX activities:
Responsible for various monthly close activities, including accounting for stock-based compensation and employee stock purchase plan (ESPP), leases, contingent liabilities, debt and intangibles
Reconciles all assigned general ledger accounts and prepares journal entries
Performs administrative duties relating to the Company’s stock option and ESPP plans
Follows and maintains SOX 404 Compliance Requirements
Provides leadership and management in an effective manner consistent with Company Values towards defined Corporate Objectives
Understands Company Policy and procedure to be able to guide direct reports appropriately
Qualification
Required
Certified Public Accountant (CPA)
Bachelor's in accounting
6+ years minimum relevant experience including Big 4 public accounting and progressive accounting/auditing and SEC financial reporting experience for a large public company (market cap of $700M+)
Prior experience designing, implementing, and documenting policies and procedures—in a SOX Environment
Strong communication skills (written and oral) and a demonstrated ability to work effectively across functions
Strong analytical, organizational, and time management skills
Confidentiality and Integrity - must be able to represent and model integrity within the organization. Must possess and maintain the highest degree of security and confidentiality of information
Knowledge of Microsoft Office, particularly Word and Excel
Ability to work independently and as part of a team and maintain high ethical standards of integrity and quality
Ability of having an innovative and dynamic approach to work
A self-starter able to work independently but comfortable working in a team environment
Ability to consistently exhibit Supernus Values in interactions with employees at all levels of the organization, vendors, customers and others
Capable of performing other duties as assigned by Management
Authorized to legally work in the United States without visa sponsorship
Preferred
Master's degree
Experience with Workiva software (wDesk)
Benefits
Opportunity to participate in employee stock purchase programs
Performance-based bonus programs
Company
Supernus Pharmaceuticals, Inc.
We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Funding
Current Stage
Public CompanyTotal Funding
$689.5MKey Investors
UBSNew Enterprise Associates
2023-02-14Post Ipo Debt· $150M
2018-03-13Post Ipo Debt· $350M
2013-04-24Post Ipo Debt· $90M
Recent News
2025-12-08
Company data provided by crunchbase